Exchange: NASDAQ·Updated 05:04 AM EDT
Upcoming Earnings: Q2 '26

Reports: Aug 13Pre-Market

Estimated EPS

-$0.23

Estimated Rev

$12.24M

$ABEO Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.30 down -25.00% YoY • Reported revenue of $8.72M • Abeona Therapeutics Inc. expects current capital resources to fund operations for at least 12 months. The company plans to file an IND for ABO-701 and commence first-in-human studies in the second half of 2027.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q2 '26
-$0.23
--
--
N/A
Q1 '26
-$0.34
-$0.30
10.45%
BEAT
Q4 '25
-$0.35
-$0.36
-2.27%
MISSED
Q3 '25
-$0.28
-$0.10
64.54%
BEAT
Q2 '25
-$0.39
$1.71
538.46%
BEAT

Advertisement|Remove ads.